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Abstract
Background: Interferon-a in combination with ribavirin is the current gold standard for treatment of chronic
hepatitis C. It is unknown if the development of autoimmune thyroid disease (TD) during treatment confers an
improved chance of achieving sustained virologic response. The aim of this study is to assess the chance of
achieving sustained virologic response (SVR) in patients who developed TD during treatment when compared with
those who did not.
Methods: We performed a tertiary hospital-based retrospective nested case-control analysis of 19 patients treated
for hepatitis C who developed thyroid disease, and 76 controls (matched for age, weight, gender, cirrhosis and
aminotransferase levels) who did not develop TD during treatment. Multivariate logistic-regression models were
used to compare cases and controls.
Results: The development of TD was associated with a high likelihood of achieving SVR (odds ratio, 6.0; 95%
confidence interval, 1.5 to 24.6) for the pooled group containing all genotypes. The likelihood of achieving SVR was
increased in individuals with genotype 1 HCV infection who developed TD (odds ratio, 5.2; 95% confidence
interval, 1.2 to 22.3), and all genotype 3 patients who developed TD achieved SVR.
Conclusions: Development of TD during treatment for hepatitis C infection is associated with a significantly
increased chance of achieving SVR. The pathophysiogical mechanisms for this observation remain to be
determined.
Trial Registration: The Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRB12610000830099
Background
Hepatitis C is one of the major global causes of chronic
hepatic infections, particularly in third world countries,
and is associated with a significant rate of cirrhosis and
hepatoma. In Australia [1,2] and the United States of
America [3,4], the burden of disease is significant.
Although the incidence has come under control, the
associated sequelae unfortunately have been predicted to
increase in the coming decades [5]. Consequently, a
large and growing number of patients will be expected
to undergo treatment for hepatitis C. Of those receiving
combination treatment with interferon (IFN)-a and
ribavirin (RBV), approximately 5-10% will develop thyr-
oid-related complications [6]. Whilst there are a number
of factors in the prediction of favourable hepatic out-
come such as genotype, ethnicity, and early viral load
reduction [7,8], there are few published reports that
assess the development of thyroid disease (TD) in rela-
tion to sustained virological response (SVR). Our pre-
vious meta-analysis did not find any difference, although
this may be due to inherent differences in the published
reports [9]. The aim of this study is to investigate the
hypothesis that the development of TD in patients
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increased likelihood of attaining SVR.
Methods
Patients and control participants
We enrolled 19 patients who developed TD while
receiving combination therapy in a major tertiary refer-
ral hospital, New South Wales (NSW), Australia. These
patients had been assessed by the endocrinology team.
All were found to have thyroiditis as previously
described [10], except one who developed primary
hypothyroidism.
Patients were treated with predetermined IFN-based
treatment regimen and thyroid surveillance protocol.
Alternative causes of chronic hepatitis were excluded.
No patient had dual Hepatitis B and C. All were moni-
tored carefully for protocol adherence and had normal
thyroid functions prior to entering treatment. Monthly
reviews were performed, including those who developed
TD (as defined below) with thyrotropin (TSH) levels,
full blood counts, renal and liver function tests as pre-
viously described [10]. Thyroid autoantibodies, whilst
predictive, were not performed as it did not affect man-
agement in the event of TD development.
Because of the scarcity of reported thyroid diseases in
relation to SVR in the literature, we performed a nested
case control study using a 1:4 ratio of cases to controls.
Patients were matched for age, gender, viral load, body
weight, alanine and aspartate aminotransferase levels,
cirrhotic state and individualised IFN-a2t r e a t m e n t s
(either a2a or a2b). The cirrhotic status was determined
clinically including ultrasonography and/or compu-
terised tomography.
Therapy
All patients were treated with combination pegylated
IFN-a and RBV therapy. Pegylated IFN- a2a (fixed dose
180 ug) or pegylated IFN-a2b (weight based dose, 1.5 ug/
kg of body weight) was injected subcutaneously weekly.
Oral RBV was administered twice daily base on the
patient’sw e i g h t( 1 . 0g m ,< 7 5k g ;1 . 2g m ,> 7 5k g )f o r
patients with genotype 1 and the fixed dose (0.8 gm) for
patients with non-1 genotype. The duration of treatment
depends on the HCV genotypes; genotypes 2 and 3 were
treated for 24 weeks and types 1 and 4 for 48 weeks
respectively. Treatment was further adjudicated accord-
ing to viral load results for genotypes 1 and 4 (see below).
For genotypes 2 and 3, treatment was continued to the
end irrespective of the qualitative viral load at 4 weeks.
Thyroid disease definition
Thyroid disease was defined as having hypo- or hyper-
thyroidism, (clinically and biochemically based).
Thyrotoxicosis was defined as having TSH of <0.1 mU/
L, fT4 levels >26.0 and/or fT3 levels >6.0 pmol/L
respectively.
Hypothyroidism, including subclinical hypothyroidism,
was defined as having TSH levels >4.0 mIU/L.
Thyroiditis is defined as the triad of clinical and/or
biochemical thyrotoxicosis the current clinical setting,
with a reduced/negligible thyroid pertechnetate uptake
scan. All uptake scans were reviewed by a specialist
nuclear physician consultant. Thyroid autoantibodies
may be present but are not considered essential to the
diagnosis.
Virological Response Surveillance Protocol
The following viral load testing protocols were used
during the study:
1. Baseline quantitative HCV RNA PCR assays were
performed on all patients irrespective of genotype.
2. For genotypes 1 and 4, qualitative viral load
assays were done at weeks 4, 24, 48 and 24 weeks
after the completion of therapy. Additional quantita-
tive assay was done at week 12. Treatment was ter-
minated if there was ≤ 2 log10 reduction of viral load
compared with baseline at the 12
th week of therapy
or if the qualitative viral load was positive at the 24
th
week.
3. For genotypes 2 & 3, qualitative viral load assay
was done at week 4, 24 (at the completion of ther-
apy) and at week 24 follow-up.
SVR was defined as serum HCV-RNA being undetect-
able by polymerase chain reaction (PCR) at 24 weeks
following the completion of therapy.
Statistical Analyses
The study was designed to detect an odds ratio of 2 or
more for associations between SVR and thyroid disease
development, with 80% power. A 1:4 ratio of cases to
controls was used, with significance tests performed at a
two-tailed alpha level of 0.05. Odds ratios were adjusted
for age, weight, gender and aminotransferase levels.
Unconditional multivariate logistic-regression analysis
was used to estimated odds ratios and 95% confidence
intervals (CIs). Statistical significance was determined
using the likelihood-ratio test. Demographic data are
presented as percentage and means with standard devia-
tions (SDs). Results were also analysed using a 2 × 2
contingency table with c
2 analysis for comparison of
percentages between groups. The Fisher’s exact analysis
and continuity correction were applied when appropri-
ate. All analyses were performed using Stata 10 software
(Stata).
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All subject cases had thyroiditis as previously defined
except for one case of primary hypothyroidism and all
patients were well matched for all stated criteria, Table 1.
Sustained virologic response was observed in 84.2% of
patients who developed TD compared with 53.9% in
those who did not. The difference between proportions
was significant at 0.30 (95% Confidence Interval (CI),
0.10 - 0.50, p < 0.05).
Overall, univariate logistic regression analysis revealed
that cases which developed TD, had a 6.0 times greater
likelihood of achieving SVR compared with controls
(95% confidence interval (CI), 1.5 to 24.6). The likeli-
hood of achieving SVR was even greater for genotype 1
cases with TD versus those without TD (OR, 5.2; 95%
CI, 1.2 to 22.3), and all genotype 3 patients who devel-
oped TD also achieved SVR, Table 2.
Multivariate logistic regression analysis showed that
presence of TD and genotype was the only two variables
significantly associated with SVR. Modelling with these
two independent variables revealed that individuals who
developed TD had a 6 folds greater likelihood of achiev-
ing SVR compared with controls (95% confidence inter-
val (CI), 1.5 to 24.6).
Discussion
The prevalence of hepatitis C is now controlled in the
Western world [5] but continues to increase in third
world and developing countries due to lack of needle
exchange program and medical infrastructure. In Aus-
tralia, the numbers have stabilized and more recently
declined [2]. The current established and accepted treat-
ment for chronic hepatitis C infection is the combina-
tion of pegylated IFN-a and RBV. This treatment
regimen delivers a cure rate of approximately 50% of
cases [11]. The favourable factors in response to treat-
ment include genotypes (2 and 3 genotypes have better
response), compliance, duration of treatment and early
Table 1 Characteristics of 95 patients and separate case/control subjects
All Patients Cases Controls P-values
TD No TD 95% CI
N = 95 N = 19 N = 76
Demographic factors
Female gender - number (%) 55 (57.9%) 11 (57.9%) 44 (57.9%) NSS
Mean age (years) ± SD 47 ± 8 47 ± 8 48 ± 7 NSS
Weight (kg) ± SD 69.7 ± 10.1 70.6 ± 8.5 69.8 ± 10.7 NSS
Hepatic factors
Cirrhosis - number (%) 5 (5.3%) 1 (5.3%) 4 (5.3%) NSS
ALT (<45 U/L) ± SD 54 ± 24 56 ± 26 53 ± 25 NSS
AST (1-30 U/L) ± SD 39 ± 11 41 ± 12 38 ± 12 NSS
Virologic factors
Genotypes - number (%)
￿ 1 55 (58.0%) 11 (58.0%) 44 (58.0%) NSS
￿ 3 40 (42.0%) 8 (42.0%) 32 (42.0%) NSS
Viral Load
- At baseline (log IU/mL) ± SD 6.44 ± 0.52 6.22 ± 0.56 6.64 ± 0.53 NSS
Treatment regimens - number (%)
IFN-a2a 55 (57.9%) 11 (57.9%) 44 (57.9%) NSS
together with
Ribavirin
1.0 gm (patients ≤ 75 kg) 20 (36.4%) 4 (36.4%) 16 (36.4%)
1.2 gm (patients >75 kg) 15 (27.3%) 3 (27.3%) 12 (27.3%)
0.8 gm 20 (36.4%) 4 (36.4%) 16 (36.4%)
IFN-a2b 40 (42.1%) 8 (42.1%) 32 (42.1%) NSS
together with
Ribavirin
1.0 gm (patients ≤ 75 kg) 10 (25.0%) 2 (25.0%) 8 (25.0%)
1.2 gm (patients >75 kg) 10 (25.0%) 2 (25.0%) 8 (25.0%)
0.8 gm 20 (50.0%) 4 (50.0%) 16 (50.0%)
Results are expressed as Means ± Standard Deviations (SDs). CI, Confidence Intervals; IFN, Interferon; NSS, Non Statistically Significant; ALT, Alanine
Aminotransferase, AST; Aspartate Aminotransferase.
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tors consist of lower body mass index, lack of co-exist-
ing liver disease and ethnicity (Asians and Caucasians
have a higher SVR than African Americans) [7]. The
relationship between TD and SVR had been scarcely
addressed and in our solitary meta-analysis, the outcome
was negative [9].
Hypothetically, when treatment is delivered, the
immune system is stimulated sufficiently in an attempt
to eradicate the virus and in the process may also be
intense enough to trigger TD, as an unintended conse-
quence. Because the presence of TD may signify a
supercharged and heightened immune response which
in turn increases the chance of eradicating the virus.
Studies have shown that in patients who developed TD,
immune marker levels such as Interleukin-6 (IL-6),
Tumor Necrosis Factor-alpha (TNF-a) and chemokines
are relatively higher and thus in the process may poten-
tially be more effective at achieving SVR [12]. Further-
more, the presence of thyroid hormones in vitro also
potentiates the antiviral action of IFN in cultured
human cells [13]. This hypothesis was observed in our
previous report in which all 11 IFN-related thyroid
cases achieved SVR [10]. However, a subsequent meta-
analysis failed to find any relationship although this
might be due to inherent differences within the various
reports [9]. This additional nested case control study in
which the cases were matched in a ratio of 1 case to 4
controls finds further supportive evidence that the
development of TD in HCV patients whilst undergoing
combination with RBV and IFN-a treatment is a favor-
able prognostic factor for achieving SVR. It is reassuring
that other factors are matched including age, gender,
weight, viral load, cirrhosis and transaminase levels;
some of which can influence final SVR status. It is also
interesting that there was one primary hypothyroid case
which was clearly not the hypothyroid phase of the thyr-
oiditis. In this case, the patient responded well to rou-
tine thyroxine supplement.
The viral kinetic responses bear little relationship to
the development of TD. It is not possible to assess the
relationship between the early viral response (EVR), its
associated viral load and the timing of TD development.
This is because TD tends to develop approximately at
the 18
th week of treatment [10]. Furthermore, the criti-
cal end-point of this report is the assessment of SVR,
irrespective of other landmark viral load studies during
treatment. However, end of treatment responses (ETR)
appear to confirm previous observation that it is often a
reliable predictor of SVR. Most patients who achieved
ETR also completed SVR except for the two genotype 1
patients who relapsed as defined by failure to achieve
SVR. There was a 6-fold increase in the chance of
achieving SVR with TD development for the pooled
Table 2 Sustained Virologic Responses (SVR), Odds Ratios (OR) and 95% Confidence Intervals (CI) analyses for all
patients, genotype 1, 3 and regimen-specific subgroups
GENOTYPE 1 ( N = 55)
Treatment regimens Pegylated IFN-a2a and
RBV 1000 mg
Pegylated IFN-a2a and
RBV 1200 mg
Pegylated IFN-a2b and
RBV 1000 mg
Pegylated IFN-a2b and
RBV 1200 mg
Control
16
TD
4
Control
12
TD
3
Control
8
TD
2
Control
8
TD
2
EVR* Not applicable (see text)
ETR - number (%) 9
(56.3%)
3
(75.0%)
9
(75.0%)
3
(100.0%)
4
(50.0%)
2
(100.0%)
5
(62.5%)
2
(100.0%)
SVR - number (%) 8
(50.0%)
3
(75.0%)
7
(58.3%)
2
(66.6%)
4
(50.0%)
2
(100.0%)
5
(62.5%)
2
(100.0%)
GENOTYPE 3 (N = 40)
Treatment regimens Pegylated IFN-a2a and RBV 800 mg Pegylated IFN-a2b and RBV 800 mg
Control
N=1 6
TD
N=4
Control
N=1 6
TD
N=4
EVR* Not applicable (see text)
ETR - number (%) 16
(100.0%)
4
(100.0%)
16
(100.0%)
4
(100.0%)
SVR - number (%) 16
(100.0%)
4
(100.0%)
16
(100.0%)
4
(100.0%)
SVR for genotype 1: Odds Ratio, 95% CI 5.2, 1.2 to 22.3
SVR for genotype 3 Control (n = 32) 100.0% TD (n = 8 ) 100.0%
All 40 cases achieved SVR making the combination of Genotype 3 and TD a perfect predictor of SVR
in this group.
Treatment related SVR IFN-a2a vs IFNa2b Non Statistically Significant
OVERALL SVR: ODDS RATIO, 95% CI 6.0, 1.5 to 24.6
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confidence interval, 1.5 to 24.6). The likelihood of
achieving SVR was increased in individuals with geno-
type 1 HCV infection who developed TD (odds ratio,
5.2; 95% confidence interval, 1.2 to 22.3). All genotype 3
patients who developed TD achieved SVR. Although our
control cohort has a SVR rate of 100%, the overall
reported and accepted rate approximates 80%, perhaps
suggesting an additional synergistic effect in this geno-
type subgroup. Because of this overall high response
rate and in order to quantify this amplified increment,
there would need to be a much larger cohort. This is
unlikely to be achievable given the low incidence of true
TD occurring in this setting.
Whilst the thyroid gland is clearly implicated in this
study, it remains undetermined whether thyroiditis is a
mediator or the result of processes leading to SVR. While
the development of a more effective immune response to
HCV may unmask underlying thyroid autoimmune ten-
dencies, it is also possible that acute exposure to supra-
physiological concentrations of thyroid hormones (THs)
may confer favourable immunomodulating activities
leading to SVR. It is not yet known if the behaviour of
the thyroid conditions in this setting is any different from
those arising de novo and hence provides differing influ-
ences on the final hepatitic viral status.
HCV infection results in the induction of IFN-a and
-b production as part of the innate immune response
[14], with subsequent activation of natural killer cells,
maturation and proliferation of dendritic cells, prolifera-
tion of memory T cells, and prevention of T-cell apop-
tosis [15]. These effects are important in the mediation
o fah e i g h t e n e dt e n d e n c yt o w a r do r g a n - s p e c i f i ca u t o i m -
munity (including TD) in patients with HCV. The addi-
tion of exogenous IFN-a potentiates the risk of
inflammatory autoimmunity in an already vulnerable
and primed thyroid gland.
The exposure to the two different forms of IFN-a may
be a potential confounder in eliciting SVR. These two
IFNs differ significantly in their pegylation characteris-
tics which may translate into their pharmacokinetics
and biological activity. Recent reports indicated that
there was a slightly higher SVR rate with pegylated IFN-
a2a compared with a2b [16]. However, recent practice
guidelines did not distinguish between the two in their
recommendations [17-19]. There appears to be insuffi-
cient data to guide preference of one over the other.
Similarly, our findings do not indicate any difference in
SVR with regards to the two types of IFN-a, but again
this is due to the small numbers.
The second potential influencing factor is the expo-
sure to THs. Normal levels are unlikely to be effective
as all other euthyroid and treated patients would
o t h e r w i s eh a v en o r m a lc i r c u lating levels. However, the
presence of THs in vitro also potentiates the antiviral
action of IFN in cultured human cells (13). In the pre-
sence of IFN, THs can enhance the immunomodulation
such as HLA-DR antigen expression (15). It is therefore
possible but highly speculative that the favorable out-
come seen in these patients is related to the exposure to
supraphysiological concentrations of THs. However, it is
equally possible that THs are not involved but is a mere
para-phenomenon in a vigorous and exaggerated
response to IFN therapy.
Finally, the recent discovery of the association between
single nucleotide polymorphisms (SNPs) near the inter-
leukin (IL) 28B gene locus showed that this plays an
important part in the spontaneous recovery, response to
treatment and attaining SVR from HCV infection
[20-23]. This SNPs may reflect differential levels of the
immunomodulating cytokine IFN-l-3, but the possibility
that individuals at higher risk of TD development har-
bor favorable SNPs remains to be explored [24].
One of the shortcomings of this report is the small
sample size, due primarily to the low prevalence of the
condition. This was a major determinant of the choice
of study design, with nested case-control studies offering
important data on relatively uncommon end-points with
little potential for additional bias. Nevertheless, colla-
boration with prominent centers would potentially allow
prospective designs to be pursued, hence enhancing the
power of the study; such studies would require standar-
dization of thyroid surveying and definitions of thyroid
disease. Secondly, there may be different genetic or
regional differences as other reports, albeit retrospective,
failed to find such a consistent pattern of SVR amongst
TD cases [25-27]. The sampling of both cases and con-
trols from the same patient cohort reduced the chance
of selection bias.
Clinical implications
The finding from this study tentatively raises the ques-
tion of whether thyroxine might be useful as an adju-
vant addition to the treatment armamentarium. It is
critical that this finding is confirmed (or refuted) by lar-
ger and independent studies because recent data sug-
gested that in HCV cases with SVR, cirrhosis and its
associated morbidities can be reversible [28].
Conclusions
This nested case control study strongly indicates that
TD is associated with a higher chance of achieving SVR,
especially in genotype 1. This association mandates lar-
ger prospective multicentre trials to conclusively address
this hypothesis if thyroxine is to be considered a poten-
tial adjuvant to current treatment regimen.
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